Reverse Translating Resmetirom’s Clinical Success to Inform the Next Generation of Antifibrotic Development
1:00 pm - Thursday 3rd December 2026
- Examining what the resmetirom clinical programme and post-approval experience have revealed about fibrosis regression, MASH resolution, and the characteristics of patients most likely to benefit
- Translating insights from serial biopsy, non-invasive testing, and longitudinal treatment response back into research to refine target validation, biomarker strategies, and preclinical models
- Understanding which elements of the development pathway could be applied across other fibrotic indications
- Exploring how emerging clinical and real-world data can guide lifecycle development, combination strategies, and the identification of additional patient populations where the underlying biology may be relevant
